Infektionsprophylaxe bei neutropenischen Patienten

W. V. Kern; J. Beyer; A. Böhme; D. Buchheidt; O. Cornely; H. Einsele; J. Kisro; W. Krüger; G. Maschmeyer; M. Ruhnke; C. A. Schmidt; S. Schwartz; H. Szelenyi

doi:10.1055/s-2000-9552

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2000; 125(51/52): 1582-1588
DOI: 10.1055/s-2000-9552

Aus Fachgremien & Konsensuskonferenzen

Infektionsprophylaxe bei neutropenischen Patienten

Leitlinien der Arbeitsgemeinschaft Infektionen in der Hämatologie und OnkologieW. V. Kern¹ , J. Beyer ² , A. Böhme³ , D. Buchheidt⁴ , O. Cornely ⁵ , H. Einsele⁶ , J. Kisro⁷ , W. Krüger ⁸ , G. Maschmeyer⁹ , M. Ruhnke¹⁰ , C. A. Schmidt ¹⁰ , S. Schwartz¹¹ , H. Szelenyi¹¹ , für die Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie der DGHO

¹Medizinische Klinik und Poliklinik, Universitätsklinikum Ulm
²Abteilung Hämatologie und Onkologie, Klinikum der Philipps-Universität Marburg
³Medizinische Klinik III, J. W. Goethe-Universität, Frankfurt/Main
⁴III. Medizinische Klinik, Klinikum Mannheim, Ruprecht-Karls-Universität Heidelberg
⁵Klinik I für Innere Medizin, Universitätsklinikum, Universität zu Köln
⁶Medizinische Klinik und Poliklinik, Univiersitätsklinikum Tübingen
⁷Medizinische Klinik I, Medizinische Universität zu Lübeck, Lübeck
⁸Abteilung Onkologie-Hämatologie, Universitätskrankenhaus Eppendorf, Hamburg
⁹Robert-Rössle-Klinik, Charité, Berlin
¹⁰Campus Virchow-Klinikum, Charité, Berlin
¹¹Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin

Abstract

Volltext

Referenzen

Literatur

1 Anderson H, Scarffe J H, Sutton R N. et al . Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomized double blind, placebo controlled trial. Br J Cancer. 1984; 50 45-49
2 Barriga F J, Varas M, Potin P. et al . Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Med Pediatr Oncol. 1997; 28 196-200
3 Bergmann O J, Ellermann-Eriksen S, Mogensen S C, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myloid leukemia: randomized, double-blind, placebo-controlled trial. Brit Med. 1995; 310 1169-1172
4 Bergmann O J, Mogensen S C, Ellermann-Eriksen S, Ellegaard J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myloid leukemia: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1997; 15 2269-2274
5 Bodey G P. Antimicrobial prophylaxis for infection in neutropenic patients. In: Remington JS, Swartz MN (eds.): Current clinical topics in infectious diseases McGraw-Hill Book Co, New York 1988: 1-43
6 Bow E J. Infection risk and cancer chemotherapy: The impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignacies. J Antimicrob Chemother. 1998; 41 (D) 1-5
7 Cruciani M, Rampazzo R, Malena M. et al . Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis. 1996; 23 795-805
8 Elliot T S, Faroqui M H, Armstrong R F, Hanson G C. Guidelines for good practice in central venous catheterization. J Hosp Infect. 1994; 28 163-176
9 Engels E, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol. 1998; 16 1179-1187
10 Gluckman E, Lotsberg J, Devergie A. et al . Prophylaxis of herpes infections after bone marrow transplantation by acyclovir. Lancet. 1983; 2 706-708
11 Gotzsche P V, Johansen H K. Meta-analysis of prophylactic or empirical antifugal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. Brit Med. 1997; 314 1238-1244
12 Greene J N. Catheter-related complications of cancer therapy. Infect Dis Clin North Am. 1996; 10 255-259
13 Gubbins P O, Bowman J L, Penzak S R. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacother. 1998; 18 549-564
14 Hann I M, Prentice H G, Blacklock H A. et al . Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: Randomized double-blind trial. Br Med. 1983; 287 384-388
15 Jansen B. Current approaches to the prevention of catheter-related infections. In: Seifert H, Jansen B, Farr BM (eds.). Catheter-related infections Marcel Dekker, New York 1997: 411-446
16 Kern W V. Epidemiology of fluoroquinolone-resistant Escherichia coli among neutropenic patients. Clin Infect Dis. 1998; 27 235-237
17 Lim S H, Smith M P, Machin S J, Goldstone A H. A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for harmatological malignancies. Eur J Haematol. 1993; 54 10-13
18 Ljungman P, Hagglund H, Bjorkstrand B. et al . Perioperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: A randomized, controlled study. Support Care Cancer. 1997; 5 485-488
19 Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev. 1997; 10 477-504
20 Martino R, Martinez C, Brunet S. et al . Tuberculosis in bone marrow transplant recipients: Report of two cases and review of the literature. Bone Marrow Transplant. 1996; 18 809-812
21 Menichetti F, Del Favero A, Martino P. et al . Itraconazole oral solution as prophylaxis for fungal infection in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind multicenter trial. Clin Infect Dis. 1999; 28 250-255
22 Murphy M, Brown A E, Sepkowitz K A. et al . Fluoroquinolone prophylaxis for the prevention of bacterial infection in patients with cancer - is it justified?. Clin Infect Dis. 1997; 25 346-347
23 Nucci M, Biasoli I, Akiti T. et al . A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis. 2000; 30 300-305
24 Rackoff W R, Weiman M, Jakobowski D. et al . A randomized controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr. 1995; 127 147-151
25 Riley D K, Pavia A T, Beatty P G. et al . The prophylactic use of low-dose amphothericin B in bone marrow transplant patients. Am J Med. 1994; 97 509-514
26 Rotstein C, Bow E J, Laverdiere M. et al . Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999; 28 331-340
27 Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: A 20 year retrospective review. Bone Marrow Transplant. 1997; 19 467-470
28 Ruhnke M, Beyer J. Antimykotische Prophylaxe bei neutropenischen und immunsupprimierten Patienten. Med Klin. 1997; 92 28-36
29 Russell J A, Poon M C, Jones A R. et al . Allogeneic bone marrow transplantation without protective isolation in adults with malignant disease. Lancet. 1992; 339 38-40
30 Saral R, Ambinder R F, Burns W H. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983; 99 773-776
31 Saral R, Burns W H, Laskin O L. et al . Acyclovir prophylaxis of herpes-simplex-virus infection. N Engl J Med. 1981; 305 63-67
32 Schwartz S, Behre G, Heinemann V. et al . Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective, randomized, multicenter trial. Blood. 1999; 93 3654-3661
33 Sheretz R J, Belani A, Kramer B S. et al . Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987; 83 709-718
34 Slavin M A, Osborne B, Adams R. et al . Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995; 171 1545-1552
35 Uzun O, Anaissie E J. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood. 1995; 86 2063-2072
36 Van Burik J H, Leisenring W, Myerson D. et al . The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine. 1998; 77 246-254
37 Vassilomanolakis M, Plataniotis G, Koumakis G. et al . Central venous catheter-related infections after bone marrow transplantation in patients with malignancies: A prospective study with short-course vancomycin prophylaxis. Bone Marrow Transplant. 1995; 15 77-80
38 Wade J C, Newton B, Fluornoy N, Meyers J D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984; 100 823-828
39 Wald A, Leisenring W, van Burik J -A, Bowden R A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 115 1459-1466
40 Walsh T J, Lee J W. Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis. 1993; 17 468-480
41 Withington S, Chambers S T, Beard M E. et al . Invasive aspergillosis in severely neutropenic patients over 18 years: Impact of intranasal amphotericin B and HEPA filtration. J Hosp Infect. 1998; 38 11-18
42 Working Party Report . Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: A review and recommendations. J Antimicrob Chemother. 1993; 32 5-21
43 Young L S. Antimicrobial prophylaxis in the neutropenic host: Lessons of the past and perspectives for the future. Eur J Clin Microbiol Infect Dis. 1988; 7 93-97
44 Henrickson K J, Axtell R A, Hoover S M. et al. . Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxa-cin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin oncol. 2000; 18 1269-1278

Korrespondenz

Priv.-Doz. Dr. Winfried V. Kern

Medizinische Universitätsklinik und Poliklinik

89070 Ulm

Telefon: 0731/5024423

Fax: 0731/5024488

eMail: winfried.kern@medizin.uni-ulm.de